

RECEIVED

JUN 24 2002

TECH CENTER 1600/2900

PATENT

#12 a
xli
6/26/02



Attorney's Docket No. 35052/204373 (5052-53)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:	Walsh et al.	Confirmation No.:	7095
Appl. No.:	09/689,430	Group Art Unit:	1632
Filed:	October 12, 2000	Examiner:	Q. Li
For:	ADENO-ASSOCIATED VIRUS VECTORS ENCODING FACTOR VIII AND METHODS OF USING THE SAME		

June 12, 2002

Commissioner for Patents
Washington, DC 20231

AMENDMENT

Sir:

In response to the Office Action mailed December 12, 2001, Applicant respectfully requests reexamination and reconsideration of the above-identified application in view of the following amendments and remarks.

In The Claims:

Please cancel claims 21-57 without prejudice to or disclaimer of the subject matter contained therein. These claims will be prosecuted in a continuation application.

Please amend claim 18 to read as follows:

- Sub B4*
18. A recombinant adeno-associated virus (rAAV) vector comprising a heterologous nucleotide sequence encoding a B-domain deleted factor VIII operably linked with an enhancer, wherein said nucleotide sequence is selected from the group consisting of:
- (a) the nucleotide sequence given as nucleotides 419 to 4835 of the nucleotide sequence set forth in SEQ ID NO:1,
 - (b) a nucleotide sequence that hybridizes to the nucleotide sequence of (a) under conditions of high stringency and which encodes a biologically active B-domain deleted factor VIII; and
- et*